



## Eli Lilly and Co / LLY

Equity | Generated Oct 6, 2026 11:31 PM EDT

|                                    |                                    |                                           |                                     |
|------------------------------------|------------------------------------|-------------------------------------------|-------------------------------------|
| Current price<br><b>\$1,158.96</b> | Daily move<br><b>+15.84 +1.39%</b> | Bid / Ask<br><b>\$1,157.51/\$1,161.00</b> | Previous close<br><b>\$1,143.12</b> |
|------------------------------------|------------------------------------|-------------------------------------------|-------------------------------------|

|                   |                          |
|-------------------|--------------------------|
| Market            | NYSE                     |
| Industry          | Pharmaceuticals          |
| Market data as of | Oct 6, 2026 11:31 PM EDT |

## JW Intelligence Report

Complete | 3 of 3 sections | Oct 6, 2026 6:50 PM EDT

|                                      |                                      |                                     |                                       |
|--------------------------------------|--------------------------------------|-------------------------------------|---------------------------------------|
| JW Rank<br><b>77.1 / 100</b>         | Rank label<br><b>Constructive</b>    | Confidence<br><b>high</b>           | IV percentile<br><b>78 / 100</b>      |
| Model reference<br><b>\$1,148.00</b> | Upside scenario<br><b>\$1,220.00</b> | Risk reference<br><b>\$1,120.00</b> | Wheel strategy fit<br><b>85 / 100</b> |

|                               |                                  |
|-------------------------------|----------------------------------|
| Options stance                | bullish                          |
| Tail-risk safety              | 56 / 100                         |
| JW Rank data coverage / as of | 100.0%   Oct 6, 2026 6:50 PM EDT |

### Key insight

LLY Shows Bullish Signs Despite Recent Pullback

### Market read

LLY is showing bullish signs despite a recent pullback. The stock price rebounded intraday towards 1160 after a flat-to-soft prior close, holding above the 200-day moving average and displaying positive momentum indicators. Recent catalysts include FDA approvals for experimental cancer treatments and positive data from clinical trials for diabetes drugs. Analyst consensus remains bullish with targets clustered near 1312-1329. However, upcoming earnings on October 29th could significantly impact the stock price.

### Strategy context

The upcoming earnings event on October 29th presents an opportunity for traders to position themselves accordingly.



## JW AI conclusions

Short- and medium-term model interpretation

AI context bias

**Bullish**

AI analysis updated

**Oct 6, 2026 2:19 PM EDT**

### Short-term scenario

Tactical neutral-to-bullish bias only on weakness, not a chase of today's bounce. 1-3 week window includes the Oct 29 earnings event, so position size should assume a volatility spike. Prefer defined risk over directional conviction. This is not a recommendation; levels are scenario planning only.

### Three-month outlook

Base case is modestly constructive if Mounjaro/Zepbound volume growth, broader coverage, and pipeline updates (oral GLP-1 and next-gen combinations) continue to support the raised 2026 revenue framework, with analyst targets still implying mid-teens upside from here over a longer horizon. Offsetting risks are a rich trailing multiple, heavy dependence on the obesity/diabetes franchise, competition, pricing and payer dynamics, and any disappointment in Q3 results or guidance. A reasonable planning range over three months is roughly 1100-1300, with path highly path-dependent on the Oct 29 report. Uncertainty is high: earnings, competitive data, policy/coverage news, or a broader risk-off move in healthcare can dominate technicals and consensus targets. Past performance and analyst targets are not guarantees of future results.

### Market sentiment

Recent X discussion is sparse and mixed-to-cautiously constructive rather than euphoric. Posts note continued long-term confidence in the healthcare growth and GLP-1/pipeline story, but also flag the valuation premium and a preference to scale in on dips rather than chase. There is visible options interest around the upcoming earnings window and occasional technical caution calling for lower levels if momentum fails. Engagement on most recent LLY-specific posts is low. Uncertainty: X samples are noisy, often promotional, and not representative of institutional positioning; sentiment can reverse quickly around headlines or the Oct 29 print.

### Supporting evidence

LLY rebounded intraday towards 1160 after a flat-to-soft prior close. | The stock is holding above the 200-day moving average (near 1074-1075). | Positive momentum indicators include RSI(14) printing in the low-to-mid 40s to around 50, indicating neutral rather than oversold or overbought conditions. | Recent catalysts include FDA approvals for experimental cancer treatments and positive data from clinical trials for diabetes drugs.


### Risk watch

Earnings on October 29th could significantly impact the stock price. | Valuation is rich with a trailing P/E of roughly 38-39x.



Enhanced price structure

45 trading days with volume, model levels and current technical reference bands




45 complete trading-session observations



JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum

bullish\_recovery

Institutional flow

Above MVWAP

Structure

Above 200D trend

Volatility

medium



## Decision indicators

Detailed momentum, institutional and structural observations

### Momentum kinematics

Direction, velocity and oscillator state

|                                |                                                |
|--------------------------------|------------------------------------------------|
| Current read                   | BULLISH RECOVERY   neutral   MACD decelerating |
| Trend signal                   | BULLISH RECOVERY                               |
| RSI signal                     | neutral                                        |
| RSI (7 / 14 / 21)              | 49.51 / 48.42 / 48.82                          |
| RSI velocity                   | 1.15                                           |
| MACD line / signal / histogram | -3.92 / - / -3.85                              |
| MACD acceleration              | -0.82                                          |
| Stochastic K / D               | 18.29 / 20.38                                  |

### Institutional footprints

Volume-weighted cost, price location and flow

|                          |                                               |
|--------------------------|-----------------------------------------------|
| Current read             | Above institutional MVWAP   Accumulation bias |
| Institutional flow       | 0.51                                          |
| 20-day MVWAP             | \$1,155.76                                    |
| Price vs 20-day MVWAP    | +0.28%                                        |
| Daily reference VWAP     | \$1,158.18                                    |
| Price vs daily reference | +0.07%                                        |
| Volume                   | 1.09M                                         |

### Structural context

Long-term trend and volatility boundaries

|                      |                                               |
|----------------------|-----------------------------------------------|
| Current read         | Above 200-day trend   Positive macro velocity |
| Macro velocity       | 0.18                                          |
| 20-day / 200-day SMA | \$1,152.58 / \$1,074.84                       |
| Bollinger range      | \$1,110.76 - \$1,194.41                       |
| Bollinger position   | 0.559                                         |



## Options and volatility intelligence


Structure, premium conditions and principal risks

|          |               |       |        |
|----------|---------------|-------|--------|
| IV rank  | IV percentile | VVIX  | SKEW   |
| 67 / 100 | 79 / 100      | 82.16 | 143.04 |

|                                 |                                                   |
|---------------------------------|---------------------------------------------------|
| Market regime                   | Calm                                              |
| Tail-risk regime                | NORMAL TAIL RISK                                  |
| Term structure                  | backwardation                                     |
| Term slope                      | -4.48 pts                                         |
| Skew read                       | balanced                                          |
| Liquidity / quote coverage      | 100.0%                                            |
| Options Snapshot IV sources     | ATM: option chain   Rank/percentile: fundamentals |
| Options Snapshot IV observed at | Oct 6, 2026 2:53 PM EDT                           |
| Options data quality            | Coverage 88.9%                                    |

## Option term structure

ATM implied-volatility curve by days to expiration



| EXPIRATION | DTE | ATM IV | STATE |
|------------|-----|--------|-------|
| 2026-10-09 | 3   | 35.2%  | -     |
| 2026-10-16 | 10  | 31.9%  | -     |
| 2026-10-23 | 17  | 30.7%  | -     |




## Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

### Bull Put Spread reference


Short \$1,135.00 | Long \$1,130.00 | Width \$5.00 | Net credit \$1.20



Max profit \$120.00 | Max loss -\$380.00 | Break-even \$1,133.80 | Per contract at expiry

### Bear Call Spread reference

Short \$1,185.00 | Long \$1,190.00 | Width \$5.00 | Net credit \$1.23



Max profit \$123.00 | Max loss -\$377.00 | Break-even \$1,186.23 | Per contract at expiry

## Event and tail-risk context

Known event windows and broad volatility conditions

|                        |              |
|------------------------|--------------|
| Next earnings date     | 2026-10-29   |
| Earnings IV-crush risk | NOT MEASURED |
| VIX                    | 15.02        |
| VVIX                   | 82.16        |
| SKEW index             | 143.04       |
| Observation confidence | high         |
| Option quote quality   | reliable     |
| Contracts observed     | 142          |



## Event and tail-risk context (continued)

Known event windows and broad volatility conditions

| FIELD                 | VALUE |
|-----------------------|-------|
| Contracts with quotes | 142   |

## Strategy fit

Generalized structure fit; not a personalized recommendation

### Market structure

LLY is showing bullish signs despite a recent pullback. The stock price rebounded intraday towards 1160 after a flat-to-soft prior close, holding above the 200-day moving average and displaying positive momentum indicators. Recent catalysts include FDA approvals for experimental cancer treatments and positive data from clinical trials for diabetes drugs. Analyst consensus remains bullish with targets clustered near 1312-1329. However, upcoming earnings on October 29th could significantly impact the stock price.

### Options context

LLY Shows Bullish Signs Despite Recent Pullback

### Wheel context

The upcoming earnings event on October 29th presents an opportunity for traders to position themselves accordingly.

### Observed evidence

LLY rebounded intraday towards 1160 after a flat-to-soft prior close. | The stock is holding above the 200-day moving average (near 1074-1075). | Positive momentum indicators include RSI(14) printing in the low-to-mid 40s to around 50, indicating neutral rather than oversold or overbought conditions. | Recent catalysts include FDA approvals for experimental cancer treatments and positive data from clinical trials for diabetes drugs.

### Principal risks to monitor

Earnings on October 29th could significantly impact the stock price. | Valuation is rich with a trailing P/E of roughly 38-39x.



## Fundamentals and events

Business quality, valuation and upcoming event context

|                              |                  |
|------------------------------|------------------|
| Market capitalization        | P/E (TTM)        |
| <b>\$1.08T</b>               | <b>40.81</b>     |
| ROE                          | Revenue growth   |
| <b>92.6%</b>                 | <b>31.7%</b>     |
| EPS growth                   | Operating margin |
| <b>49.3%</b>                 | <b>42.2%</b>     |
| Net profit margin            | Gross margin     |
| <b>33.5%</b>                 | -                |
| Free cash flow CAGR          | Debt / equity    |
| <b>5.9%</b>                  | <b>1.60</b>      |
| Dividend yield               | Beta             |
| <b>0.8%</b>                  | <b>0.42</b>      |
| 52-week range                |                  |
| <b>\$783.85 - \$1,292.65</b> |                  |

## Company or fund profile

Issuer identity and classification

|                         |                                           |
|-------------------------|-------------------------------------------|
| Name                    | Market                                    |
| <b>Eli Lilly and Co</b> | <b>NYSE</b>                               |
| Industry                | Country                                   |
| <b>Pharmaceuticals</b>  | <b>US</b>                                 |
| Currency                | IPO date                                  |
| <b>USD</b>              | <b>1970-07-09</b>                         |
| Shares outstanding      | 52-week return                            |
| <b>941.74M</b>          | <b>39.4%</b>                              |
| Book value per share    | Revenue per share                         |
| <b>\$35.98</b>          | <b>\$89.14</b>                            |
| Website                 | <a href="https://lilly.com">lilly.com</a> |



## Latest strategy observation

Most recent shared general market signal available when this report was generated

|                                                          |                         |
|----------------------------------------------------------|-------------------------|
| <b>LLY Covered Call signal</b>                           | Oct 6, 2026 9:47 AM EDT |
| <b>Covered Call   2026-10-09</b>                         |                         |
| At signal \$1,170.15   Current \$1,158.96                |                         |
| <b>SHORT     Option \$1,165.00 B \$17.75 / A \$20.00</b> |                         |
| <b>Conservative   CR \$18.88</b>                         |                         |



Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

|                                   |                               |
|-----------------------------------|-------------------------------|
| ATR                               | \$31.92                       |
| ATR as % of price                 | 2.8%                          |
| Volatility environment            | medium                        |
| Current IV                        | 40.6%                         |
| IV rank                           | 66 / 100                      |
| IV percentile                     | 78 / 100                      |
| Technical Snapshot IV source      | Private fundamentals snapshot |
| Technical Snapshot IV observed at | Oct 6, 2026 7:31 PM EDT       |

Technical health and risk radar

Derived indicator health and event context

|                      |                  |
|----------------------|------------------|
| Overall health       | 82 / 100         |
| Trend health         | 78 / 100         |
| Momentum health      | 88 / 100         |
| Volatility health    | 69 / 100         |
| Structure health     | 94 / 100         |
| Earnings risk / date | low   2026-10-29 |
| Macro risk           | unknown          |
| Volatility risk      | medium           |
| Structure risk       | low              |

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

|                                  |                                      |
|----------------------------------|--------------------------------------|
| SMA (20 / 50 / 200)              | \$1,152.58 / \$1,174.93 / \$1,074.84 |
| EMA (9 / 21)                     | \$1,156.95 / \$1,160.28              |
| Bollinger upper / middle / lower | \$1,194.41 / \$1,152.58 / \$1,110.76 |



Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

| FIELD                 | VALUE                   |
|-----------------------|-------------------------|
| Bollinger %B          | 0.559                   |
| True high / low       | \$1,177.07 / \$1,139.98 |
| 5-day true high / low | \$1,215.00 / \$1,136.66 |

Three-day indicator history

Short-horizon change and the underlying three-session observations

| INDICATOR | 3-DAY CHANGE | SESSION 1 / 2 / 3                   |
|-----------|--------------|-------------------------------------|
| SMA20     | 0.177        | -                                   |
| SMA50     | -0.907       | -                                   |
| MVWAP20   | 0.509        | -                                   |
| MACD      | -0.816       | -                                   |
| RSI       | 1.154        | -                                   |
| Volume    | 4267.000     | -                                   |
| ATR       | -0.097       | -                                   |
| T1        | -            | -4.20 / 1153.93 / 1165.73 / 1139.49 |
| T2        | -            | -3.04 / 1153.87 / 1164.92 / 1136.66 |
| T3        | -            | -1.48 / 1154.23 / 1158.72 / 1139.85 |



## Detailed options evidence

Supporting option-chain, execution and data-quality observations

|                                 |                                                          |
|---------------------------------|----------------------------------------------------------|
| Underlying price at observation | <b>\$1,158.68</b>                                        |
| Options Snapshot IV sources     | <b>ATM: option chain   Rank/percentile: fundamentals</b> |
| Options Snapshot IV observed at | <b>Oct 6, 2026 2:53 PM EDT</b>                           |
| Options data coverage           | <b>88.9%</b>                                             |
| SKEW regime                     | <b>HIGH TAIL RISK SKEW</b>                               |
| VVIX regime                     | <b>VVIX FLAT</b>                                         |
| Front expiration / DTE          | <b>2026-10-09   3 DTE</b>                                |
| Front at-the-money IV           | <b>35.2%</b>                                             |
| 25-delta skew                   | <b>0.84</b>                                              |
| Put / Call 25-delta             | <b>\$1,135.00 Delta -0.252 / \$1,185.00 Delta 0.253</b>  |
| Median option bid/ask spread    | <b>24.7%</b>                                             |
| Bid/ask spread                  | <b>-</b>                                                 |
| Contracts observed / quoted     | <b>142 / 142</b>                                         |

### Price context

Last Price: 1,158.68 | Bid: 1,158.68 | Ask: 1,160.14 | Previous Close: 1,143.12 | Change: 15.56 |  
Daily change: 1.36% | Update Time: 2026-10-06T14:53:50.146706-04:00 | Latest History Date: 2026-10-06  
| Latest History Price: 1,158.68

### Historical context

Trading-day sample: 60 sessions | First Date: 2026-07-14 | Latest Date: 2026-10-06 | Latest Price:  
1,158.68 | Max Drawdown 60d Percent: -12.86%

### Fundamental context

Current Iv Percent: 40.80% | Iv Rank: 66.93 | Iv Percentile: 79.28 | Next Earnings Date: 2026-10-29 |  
Ex Dividend Date: 2026-08-13



## Important disclosures

Scope, limitations, risk and permitted interpretation

### General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

### Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

### Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

### Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

### Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

### Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at [theocc.com](http://theocc.com).

Generated Oct 6, 2026 11:31 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

## Reference documents

Official product terms and standardized options disclosure

|                             |                                                                                                          |
|-----------------------------|----------------------------------------------------------------------------------------------------------|
| Jason Wheel                 | <a href="http://jasonwheel.com">jasonwheel.com</a>                                                       |
| Terms of Use                | <a href="http://jasonwheel.com/Terms">jasonwheel.com / Terms</a>                                         |
| Privacy Policy              | <a href="http://jasonwheel.com/Privacy">jasonwheel.com / Privacy</a>                                     |
| Options Disclosure Document | <a href="http://theocc.com/Options%20Disclosure%20Document">theocc.com / Options Disclosure Document</a> |